Recent observations in this laboratory suggested that urinary pyrophosphate excretion may reflect the rate of bone resorption in clinical disorders of bone metabolism (1) . Since parathyroid hormone is known to accelerate bone resorption (2, 3) , changes in parathyroid function might also be expected to be associated with parallel changes in pyrophosphate excretion. An elevated urinary excretion of pyrophosphate has been previously reported in patients with hyperparathyroidism (1) . The present studies were designed to further examine the relationship of parathyroid activity to pyrophosphate excretion.
Methods
Four different types of experiments were done: 1) Measurements of urinary pyrophosphate during periods of active bone resorption and formation. Urinary pyrophosphate, calcium, and hydroxyproline measurements were made in two patients with active Paget's disease (F.H. and D.F.) before, during, and after 12 days of relative immobilization induced by bed rest. Similar measurements were also made in two patients with hyperparathyroidism (H.G. and E.F.) before and during a 6-day interval immediately after remedial parathyroid surgery. All four subjects were studied during periods of hospitalization after 7 to 14 days adaptation to constant weighed diets containing 800 mg of P and 600 mg of Ca and devoid of fish, jello, ice cream, or other gelatin-rich foods. Urine was collected in 24-hour pools, and serial blood specimens were obtained daily.
2) Four-hour calcium infusion. Fifteen mg of calcium (as calcium glucoheptonate) per kg of body weight was infused intravenously to four patients with untreated idiopathic hypoparathyroidism (ages 21 to 37 years), two patients with hyperparathyroidism (ages 47 and 63 years), and four normal volunteers (ages 23 to 30 years). All subjects were maintained on constant dietary intakes containing 700 to 800 mg P, 500 to 600 mg Ca, and less than 10 mg of hydroxyproline in the form of protein.
On day 7 of the diet, the calcium was administered in 0.9% sodium chloride solution by constant infusion over a 4-hour period beginning at 8:00 a.m. Four-hour urine collections were initiated at 8:00 a.m. on the day before the calcium infusion and continued for the subsequent 72-hour period. Blood samples were obtained in the middle of each 4-hour collection period. Calcium glucoheptonate was also administered by continuous intravenous infusion to one patient (N.D.) with untreated idiopathic hypoparathyroidism for 4 consecutive days. The 5 days before and 5 days after the infusion served as control periods. The dosage of calcium averaged 16.2 mg per kg per day. Urine was collected in 24-hour pools, and blood samples were obtained daily.
3) Parathyroid extract administration. Aqueous PTE 1 was administered to two normal male subjects and to four patients with untreated idiopathic hypoparathyroidism. PTE was given intramuscularly at a dosage of 200 U every 8 hours for a period of 6 days. These six patients were also studied during constant dietary intakes identical to those reported above in the calcium infusion experiments. Urine samples were collected in 24-hour pools and blood samples obtained at daily intervals.
In each of the above experiments measurements of Ca, P, and creatinine were made on blood and urine. In addition, pyrophosphate and total hydroxyproline measurements were made on all urine specimens.
4) Renal arterial perfusion with parathyroid extract.
Five female mongrel dogs weighing 15 to 22 kg were anesthetized with 10 to 15 mg per kg of pentobarbital intravenously. Both renal arteries and ureters were exposed via a subdiaphragmatic abdominal approach and the ureters catheterized, thus permitting simultaneous collection of timed urine samples from both kidneys. After identification and exposure of a renal artery, the blood flow was temporarily interrupted by an appropriately placed ligature. A special cannula consisting of an 1 Eli Lilly, Indianapolis, Ind. creatinine. Serial blood specimens were drawn midway between each of the timed urine collection periods for measurements of Ca, P, and creatinine. Analytic methods. Samples of blood and urine were analyzed for Ca by flame photometry, for P by the method of Fiske and Subbarow (5), and for creatinine by the method of Bonsnes and Taussky (6) . Samples of urine were also analyzed for inorganic pyrophosphate by a previously published modification of the method of Fleisch, Bisaz, and Care (1) and for total hydroxyproline by the method of Prockop and Udenfriend (7).
Results
Hyperparathyroidism and Paget's disease. A three-to fourfold reduction in the pyrophosphaturia of subjects with hyperparathyroidism (H.G. and S.F., Table I ) was observed in the immediate postoperative period. The fall in pyrophosphate excretion was accompanied by a decrease in serum calcium, and urinary hydroxyproline, orthophosphate, and calcium. As illustrated in Figure 1 , these findings coincided with a rise in serum alkaline phosphatase during the postoperative period.
A significant rise in urinary pyrophosphate was observed in both patients with Paget's disease during the period of immobilization (D.F. and F.H., Table I ). This was followed by a gradual fall in the ambulatory postcontrol periods toward preimmobilization values. Bed rest also produced significant increments in urinary hydroxyproline and calcium in both patients with little alteration in serum calcium or urinary orthophosphate. In one patient ( Figure 2 ) a fall in serum alkaline phosphatase from 45 to 32 Bodansky U accompanied patients (N.D. and A.G., Table II ) and fell in two others (A.D. and M.R., Table II ).
The results of a prolonged 4-day calcium infusion in one hypoparathyroid subject are illustrated in Figure 4 . Coincident with a gradual rise in serum calcium from 6.2 to 12.1 mg per 100 ml, urinary pyrophosphate steadily rose from a mean control value of 1.2 to 24.6 mg P per 24 hours on the fourth infusion day. In contrast, increments in urinary orthophosphate were prompt and paralleled corresponding changes in serum inorganic phosphate. Maximal values for both serum phosphate and urinary orthophosphate were reached by the second infusion day followed by a fall in the subsequent 2-day infusion period. No consistent changes were noted in hydroxyproline excretion during this time.
As illustrated in Table II The average control urinary pyrophosphate for this group of 1.7 mg P per 24 hours rose 14-fold to 24.7 during treatment with PTE. As illustrated in Figure 4 , the PTE-induced pyrophosphaturia was prompt and persisted during the 6-day therapeutic course, returning immediately to pretreatment values the first day PTE was discontinued. During the period of PTE therapy serum phosphate fell to values ranging from 1.9 to 2.5 mg per 100 ml, and serum calcium rose to values ranging from 9.7 to 10.9 mg per 100 ml. As noted in Table III Renal arterial perfusion. The decrease in pyrophosphate excretion observed while endogenous parathyroid hormone secretion was suppressed in normal subjects by calcium infusions and the pyrophosphaturia after PTE administration to normal and hypoparathyroid subjects suggested a direct relationship between parathyroid activity and pyrophosphate excretion. Since parathyroid hormone exerts a direct influence on renal tubular phosphate transport (4), the observed alterations in pyrophosphate excretion could also have been mediated through PTE-induced changes in the renal excretion of pyrophosphate. For this reason the effect of direct renal arterial perfusion with PTE on pyrophosphate excretion was studied. The protocols of two representative perfusion experiments are shown in Table IV , and a summary of four such perfusion experiments is rise (within the first 30-minute collection period) noted in Table V. in orthophosphate excretion was observed in the When unilateral PTE-renal arterial perfusion perfused kidney in three, with gradual increments was initiated in each of four dogs, an immediate during the remainder of the perfusion period (Ta- bles IV and V and Figure 5 ). In contrast, significant increments in pyrophosphate excretion by the experimental kidney were delayed for 1 to 2 hours after the PTE infusion had begun and coincided with similar delayed increments in pyrophosphate excretion from the control saline-perfused kidney ( Figure 5 ). As noted in Table V , the control kidney shared in this delayed response to PTE with increments in orthophosphate, pyrophosphate, and hydroxyproline excretion. These characteristic delayed increments in pyrophosphate excretion by both PTE-and saline-perfused kidneys occurred in the absence of any significant differential changes in creatinine clearance or urine flow.
Discussion
Pyrophosphate, an anhydro-dimer of orthophosphate present in most body tissues, plays an integral role in cellular biosynthesis (8, 9) . It has been identified in bone by Cartier and Picard (10) and Perkins and Walker (11) and its possible role in hydroxyapatite precipitation and crystal growth reviewed by Fleisch and Bisaz (12, 13) . Recently Krane and Glimcher have also cited evidence that inorganic pyrophosphate is bound to the calcium apatite crystal (14) . Despite these observations the significance of urinary pyrophosphate and its relation to bone metabolism are still uncertain. The pyrophosphaturia previously reported in hyperparathyroidism and Paget's disease (1) suggested that pyrophosphate excretion reflected the accelerated bone resorption characteristic of these disorders. The present findings are consistent with the hypothesis that pyrophosphate excretion is also controlled to some extent by parathyroid activity. A prompt pyrophosphaturia was observed in normal and hypoparathyroid subjects during PTE administration, and conversely, a significant fall in pyrophosphate excretion occurred only in normal subjects during suppression of endogenous parathyroid hormone release by calcium infusion. That this parathyroid control is not mediated through renal phosphate regulating mechanisms is suggested by the renal arterial perfusion experiments in dogs wherein no direct effect of PTE on pyrophosphate excretion was observed (Tables IV and V, Figure 5 ).
The delayed bilateral rise in pyrophosphate excretion observed during unilateral renal arterial perfusion with PTE is consistent with a systemic effect of nonfiltered PTE. Hydroxyprolinuria has often been reported in clinical disorders of bone metabolism (1, (15) (16) (17) , and an apparent relation between parathyroid activity and urinary hydroxyproline has been defined (17) . Recent isotopic data also reveal that hydroxyproline excretion correlates well with bone resorption (18) (19) (20) . The delayed hydroxyprolinuria observed in both kidneys during unilateral renal arterial perfusion with PTE probably reflects bone resorption induced by the nonfiltered fraction of infused PTE. In view of the PTE-pyrophosphate relationship observed in man (Tables II and III) , the delayed pyrophosphaturia noted in the dog perfusion experiments may also be related to PTEinduced bone resorption.
The results of postsurgical studies in hyperparathyroidism and immobilization in Paget's disease suggest that pyrophosphate like hydroxyproline excretion derives primarily from bone resorption. In both patients with hyperparathyroidism, a prompt reduction in urinary pyrophosphate occurred postoperatively when bone destruction was presumably decreased and reparative bone forma-tion proceeding at a rapid rate as indicated by a rising serum alkaline phosphatase (Figure 1) . Hypercalciuria, hydroxyprolinuria, and a fall in serum alkaline phosphatase have been observed when patients with Paget's disease are immobilized and attributed to a combination of decreased bone formation and increased bone resorption (21, 22) . In the present study, immobilization produced a rise in urinary pyrophosphate in two subjects with active Paget's disease as well as hydroxyprolinuria and hypercalciuria ( Table I ).
As illustrated in Figure 2 , the increase in pyrophosphate excretion occurred despite a fall in bone formation rate as reflected by steadily decreasing serum alkaline phosphatase.
Comparable diurnal excretory patterns of orthoand pyrophosphate illustrated in Figure 3 and the parallel rise and fall of both ortho-and pyrophosphate during calcium infusion studies in hypoparathyroid and normal subjects, respectively, suggest that pyrophosphate excretion may also be regulated by orthophosphate excretion. Proportional increments in ortho-and pyrophosphate excretion have been observed in man during orthophosphate feeding experiments (23) (24) (25) . Russell (25) . It could also be postulated that elevations in urinary pyrophosphate relate directly to increments in the endogenous phosphate pool resulting in an accelerated formation of pyrophosphate. However, not only are the thermodynamic requirements for a direct endergonic orthophosphatepyrophbsphate transformation impractical at physiological pH (26) , but in the presence of the. widely distributed enzyme, inorganic pyrophosphatase, the pyrophosphate would disappear almost as promptly as it was formed (8) . The hypothesis that the changes in urinary pyrophosphate, illustrated for normal subjects in Table I , resulted primarily from suppression of endogenous parathyroid hormone release and decreased bone resorption rather than from secondary changes in circulating phosphate and orthophosphate excretion is strengthened by the observation that pyrophosphate excretion falls when calcium salts are administered to normal individuals despite a concomitant rise in serum phosphate (Figure 3) . Whereas the coincident fall in orthdphosphate clearance under these circumstances is attributed to an increased tubular resorption of orthophosphate (27) (28) (29) , the fall in urinary pyrophosphate probably reflects a decrease in bone resorption, since PTE has no direct effect on the renal excretion of pyrophosphate (Tables IV and V , Figure 5) .
The source of the pyrophosphate that brings about the rise in urinary levels in patients with hypoparathyroidism during calcium infusion can only be speculated upon at this time. Short term infusion of calcium salts to these patients generally produces a rise in both serum phosphate and orthophosphate clearance (29, 30) . The rise in orthophosphate excretion has been attributed in the past to the rise in serum phosphorus coincident with a decreased tubular resorption of phosphate. Recently Eisenberg has shown that the increments in orthophosphate clearance in hypoparathyroid subjects during calcium infusion are also mediated through a mechanism for phosphate homeostasis that is independent of parathyroid control (31) . As noted in Figure 4 , the increments in pyrophosphate excretion observed during a prolonged 4-day infusion in a subject with hypoparathyroidism coincided with increments in serum calcium levels rather than with changes in serum phosphate. It seems unlikely that the skeleton would yield pyrophosphate in response to hypercalcemia, since hypercalcemia should cause deposition of bone rather than resorption. The most reasonable explanation for the pyrophosphaturia observed in hypoparathyroid subjects during a period of induced hypercalcemia is that the hypercalcemia per se causes an increase in cellular pyrophosphate (possibly via an inhibition of the enzyme, inorganic pyrophosphatase) and a shift of cellular pyrophosphate to the extracellular compartment. A consequent increase in circulating pyrophosphate would then result in pyrophosphaturia. The estimated low pyrophosphate blood concentration of 10-5 mole per L (13) and lack of specificity in available quantitative methods for serum pyrophosphate presently prohibit the serum pyrophosphate measurements essential for verification of this hypothesis.
URINARY PYROPHOSPHATE AND PARATHYROID ACTIVITY
A fall in urinary pyrophosphate, orthophosphate, and hydroxyproline was observed in two patients with hyperparathyroidism during short term infusion with calcium salts (Table II) . Schwartz (32) and Nordin, Smith, and MacGregor (33) have also noted suppression of hydroxyproline excretion in subjects with hyperparathyroidism during calcium infusion studies despite the reported insensitivity of parathyroid tumors to induced hypercalcemia (27, 29) . These results suggest either that some parathyroid tumors may not be completely autonomous and their secretions alterable by physiologic stimuli or that in weakly functioning tumors the remaining normal glands may be still further suppressed by induced hypercalcemia.
Summary
Parathyroid extract administration to normal subjects and patients with hypoparathyroidism caused a significant increase in urinary pyrophosphate that reverted to pretreatment values when therapy was discontinued. A 4-hour constant infusion of calcium produced a prompt fall in pyrophosphate excretion in normal subjects but not in hypoparathyroid patients.
Unilateral renal arterial perfusion with parathyroid extract in dogs resulted in a significant prompt rise in orthophosphate and a delayed rise in pyrophosphate excretion. The latter coincided with corresponding delayed increments in orthophosphate, hydroxyproline, and pyrophosphate excretion in the contralateral control saline-perfused kidney. These observations suggest that pyrophosphate excretion is regulated by parathyroid activity and that this regulation is mediated through alterations in bone resorption.
